Len Blavatnik weighs big share purchase in Teva Pharma: Reports
Jerusalem: Billionaire businessman Len Blavatnik is looking to buy a significant stake in debt-ridden Israeli drugmaker Teva Pharmaceutical Industries Ltd, according to Israeli media reports.
Two of Israel’s leading financial news outlets, Globes and The Marker, reported on Sunday that Blavatnik has been examining a large share purchase in Teva, whose stock price hit a 17-year-low last week after the company again cut its annual profit forecast.
Officials at Blavatnik’s US-based industrial group, Access Industries, were not immediately reachable for comment. Teva, the world’s biggest generic drugs maker, declined to comment.
The Marker reported that Blavatnik was looking to acquire up to a $3 billion stake in Teva. The company has a $12.3 billion market cap.
The investment could either be done through a private stock listing, which would help Teva deal with its nearly $35 billion debt burden, or the shares could be bought from pharmaceutical firm Allergan, the report said.
Allergan received a 10% stake in Teva as part of a 2016 deal in which Teva bought its generics business for $40.5 billion. Allergan announced last week that it would begin selling down that stake.
Blavatnik’s Access has investments in real estate, chemicals, media and technology with Warner Music among its highest profile businesses. Reuters
- Farooq Abdullah asks Centre to look into condition of war widows
- Rafale jet purchase win-win partnership for both France and India: French minister
- Eris to buy Strides Shasun’s India branded business for Rs500 crore
- Demonetisation not an appropriate response to black money: Manmohan Singh
- Brexit talks at a standoff as Donald Tusk sets UK’s May an ultimatum